(Q36574234)

15 August 2017

Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk (English)

1 reference

15 August 2017

Elizabeth Barrett-Connor

10

object named as

Elizabeth Barrett-Connor

0 references

Jane A. Cauley

object named as

Jane A Cauley

2

0 references

Lori Mosca

5

object named as

Lori Mosca

1 reference

15 August 2017

3

Mary Jane Geiger

1 reference

15 August 2017

7

Nanette K Wenger

1 reference

15 August 2017

Deborah Grady

1

1 reference

15 August 2017

Marcel Kornitzer

4

1 reference

15 August 2017

Peter Collins

6

1 reference

15 August 2017

Jingli Song

8

1 reference

15 August 2017

John Mershon

9

1 reference

15 August 2017

Raloxifene Use for The Heart Trial Investigators

11

1 reference

15 August 2017

language of work or name

English

0 references

publication date

10 June 2008

1 reference

Journal of the National Cancer Institute

15 August 2017

1 reference

15 August 2017

100

1 reference

15 August 2017

12

1 reference

15 August 2017

854-861

1 reference

Results of 23,810 cases of ductal carcinoma-in-situ

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Alcohol consumption and breast cancer risk in the Women's Health Study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Cyclin D1 and breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Estrogen carcinogenesis in breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Rates of growth of human neoplasms: Part II.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Prevalence and determinants of estrogen replacement therapy in elderly women.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Lifetime recreational exercise activity and breast cancer risk among black women and white women

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Design and methods of the Raloxifene Use for The Heart (RUTH) study

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

Validation studies for models projecting the risk of invasive and total breast cancer incidence.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3559134

21 September 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN153

Physical Activity and Breast Cancer Risk: The European Prospective Investigation into Cancer and Nutrition

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN153

The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18544744

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18544744

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/JNCI/DJN153

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

18544744

1 reference